S&P 500   3,374.34 (-0.18%)
DOW   27,892.53 (-0.30%)
QQQ   272.85 (+0.36%)
AAPL   460.18 (+1.80%)
MSFT   208.89 (-0.14%)
FB   261.36 (+0.57%)
GOOGL   1,519.77 (+0.83%)
AMZN   3,172.97 (+0.34%)
NVDA   459.47 (+0.41%)
CGC   17.35 (+0.58%)
BABA   253.97 (-0.48%)
TSLA   1,626.38 (+4.61%)
GE   6.61 (-1.64%)
MU   46.31 (-4.48%)
AMD   82.20 (-0.50%)
T   29.93 (-0.83%)
F   7.04 (-0.98%)
ACB   10.29 (+5.00%)
GILD   68.22 (-0.90%)
NFLX   482.35 (+1.45%)
DIS   131.35 (-0.33%)
BAC   26.34 (-1.46%)
BA   175.18 (-0.15%)
S&P 500   3,374.34 (-0.18%)
DOW   27,892.53 (-0.30%)
QQQ   272.85 (+0.36%)
AAPL   460.18 (+1.80%)
MSFT   208.89 (-0.14%)
FB   261.36 (+0.57%)
GOOGL   1,519.77 (+0.83%)
AMZN   3,172.97 (+0.34%)
NVDA   459.47 (+0.41%)
CGC   17.35 (+0.58%)
BABA   253.97 (-0.48%)
TSLA   1,626.38 (+4.61%)
GE   6.61 (-1.64%)
MU   46.31 (-4.48%)
AMD   82.20 (-0.50%)
T   29.93 (-0.83%)
F   7.04 (-0.98%)
ACB   10.29 (+5.00%)
GILD   68.22 (-0.90%)
NFLX   482.35 (+1.45%)
DIS   131.35 (-0.33%)
BAC   26.34 (-1.46%)
BA   175.18 (-0.15%)
S&P 500   3,374.34 (-0.18%)
DOW   27,892.53 (-0.30%)
QQQ   272.85 (+0.36%)
AAPL   460.18 (+1.80%)
MSFT   208.89 (-0.14%)
FB   261.36 (+0.57%)
GOOGL   1,519.77 (+0.83%)
AMZN   3,172.97 (+0.34%)
NVDA   459.47 (+0.41%)
CGC   17.35 (+0.58%)
BABA   253.97 (-0.48%)
TSLA   1,626.38 (+4.61%)
GE   6.61 (-1.64%)
MU   46.31 (-4.48%)
AMD   82.20 (-0.50%)
T   29.93 (-0.83%)
F   7.04 (-0.98%)
ACB   10.29 (+5.00%)
GILD   68.22 (-0.90%)
NFLX   482.35 (+1.45%)
DIS   131.35 (-0.33%)
BAC   26.34 (-1.46%)
BA   175.18 (-0.15%)
S&P 500   3,374.34 (-0.18%)
DOW   27,892.53 (-0.30%)
QQQ   272.85 (+0.36%)
AAPL   460.18 (+1.80%)
MSFT   208.89 (-0.14%)
FB   261.36 (+0.57%)
GOOGL   1,519.77 (+0.83%)
AMZN   3,172.97 (+0.34%)
NVDA   459.47 (+0.41%)
CGC   17.35 (+0.58%)
BABA   253.97 (-0.48%)
TSLA   1,626.38 (+4.61%)
GE   6.61 (-1.64%)
MU   46.31 (-4.48%)
AMD   82.20 (-0.50%)
T   29.93 (-0.83%)
F   7.04 (-0.98%)
ACB   10.29 (+5.00%)
GILD   68.22 (-0.90%)
NFLX   482.35 (+1.45%)
DIS   131.35 (-0.33%)
BAC   26.34 (-1.46%)
BA   175.18 (-0.15%)
Log in

NASDAQ:EMMAEmmaus Life Sciences Stock Price, Forecast & News

$1.54
+0.04 (+2.67 %)
(As of 08/13/2020 03:49 PM ET)
Add
Compare
Today's Range
$1.41
Now: $1.54
$1.54
50-Day Range
$1.50
MA: $1.79
$2.14
52-Week Range
$0.85
Now: $1.54
$4.50
Volume19,338 shs
Average Volume23,971 shs
Market Capitalization$74.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.91
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EMMA
CUSIPN/A
CIKN/A
Phone310-214-0065

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.32 million
Book Value$2.60 per share

Profitability

Net Income$-9,590,000.00
Net Margins-489.28%

Miscellaneous

Employees28
Market Cap$74.65 million
Next Earnings DateN/A
OptionableNot Optionable
$1.54
+0.04 (+2.67 %)
(As of 08/13/2020 03:49 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EMMA News and Ratings via Email

Sign-up to receive the latest news and ratings for EMMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Emmaus Life Sciences (NASDAQ:EMMA) Frequently Asked Questions

How has Emmaus Life Sciences' stock price been impacted by COVID-19?

Emmaus Life Sciences' stock was trading at $2.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EMMA stock has decreased by 44.4% and is now trading at $1.54.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Emmaus Life Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emmaus Life Sciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Emmaus Life Sciences
.

Has Emmaus Life Sciences been receiving favorable news coverage?

News articles about EMMA stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Emmaus Life Sciences earned a coverage optimism score of -4.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Emmaus Life Sciences
.

Who are some of Emmaus Life Sciences' key competitors?

What other stocks do shareholders of Emmaus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emmaus Life Sciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Chimerix (CMRX), Entasis Therapeutics (ETTX), Provention Bio (PRVB) and Cassava Sciences (SAVA).

Who are Emmaus Life Sciences' key executives?

Emmaus Life Sciences' management team includes the following people:
  • Dr. Yutaka Niihara M.P.H., M.D., M.P.H, Chairman & CEO (Age 59)
  • Mr. Willis C. Lee, Vice Chairman & COO (Age 59)
  • Ms. Lan T. Tran M.P.H., M.P.H, Pres & Chief Admin. Officer (Age 43)
  • Mr. Yasushi Nagasaki CPA, Sr. VP of Fin. (Age 52)
  • Mr. Joseph C. Sherwood III, Chief Financial Officer

What is Emmaus Life Sciences' stock symbol?

Emmaus Life Sciences trades on the NASDAQ under the ticker symbol "EMMA."

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Emmaus Life Sciences' stock price today?

One share of EMMA stock can currently be purchased for approximately $1.54.

How big of a company is Emmaus Life Sciences?

Emmaus Life Sciences has a market capitalization of $74.65 million and generates $1.32 million in revenue each year. The company earns $-9,590,000.00 in net income (profit) each year or ($11.16) on an earnings per share basis. Emmaus Life Sciences employs 28 workers across the globe.

What is Emmaus Life Sciences' official website?

The official website for Emmaus Life Sciences is www.emmausmedical.com.

How can I contact Emmaus Life Sciences?

Emmaus Life Sciences' mailing address is 21250 Hawthorne Boulevard Suite 800, Torrance CA, 90503. The company can be reached via phone at 310-214-0065 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.